TRELLIS BIOSCIENCE Secures $9 Million in Latest Series C Funding Round

TRELLIS BIOSCIENCE secured $9 million in its latest Series C, adding another data point to the Healthcare & Life Sciences funding market.

TRELLIS BIOSCIENCE Raises $9 million in Funding

TRELLIS BIOSCIENCE RAISES $9 MILLION TO ADVANCE CLINICAL DEVELOPMENT OF CALPURBATUG (TRL1068) Trellis Bioscience secures Series C financing for TRL1068 trial Trellis Bioscience Raises $9 Million Series C to Advance.

Investors Behind the Funding

The round was backed by undisclosed investors. Capvizr tracks this investor activity alongside sector momentum, co-investor patterns, and recent comparable raises.

Company Profile and Market Context

TRELLIS BIOSCIENCE operates in Healthcare & Life Sciences. TRELLIS BIOSCIENCE's financing adds to recent private-market activity.

Strategic Use of Funds

ADVANCE CLINICAL DEVELOPMENT OF CALPURBATUG (TRL1068) Trellis Bioscience secures Series C financing for TRL1068 trial Trellis Bioscience Raises $9 Million Series C to Advance.

Looking Ahead

Trellis Bioscience secures Series C financing for TRL1068 trial

Source reference: original announcement/article.